clinical dermatology

Patch testing remains underreported
Patch testing remains underreportedPatch testing for allergic contact dermatitis in the pediatric population is performed at a higher rate than previously reported, but still grossly underreported, according to a study of the Pediatric Contact Dermatitis Registry.
Laser treatment in children
Laser treatment in childrenLaser treatments can have a significant positive impact on a child’s wellbeing. Adopt techniques to minimize anxiety for children. Some conditions can be treated when the child is older.
Propranolol equal to steroids in infantile hemangioma treatmentPrednisolone was the first-line therapy for hemangiomas for many years before propranolol was recognized as the treatment of choice in infantile hemangiomas. Both modalities have a 90% response rate.
The neonatal microbiomeCesarean section newborns have a slightly delayed microbiome response. The richness of microorganisms is less than vaginally delivered newborns by 3-7 days. Use products on neonatal skin that are designed for neonatal skin.
Topical antibiotics and antiseptics disrupt the skin microbiomeDelayed diagnosis of PsA can lead to poor outcomes. Access to care elusive to some patients due to doctor shortage. Models of care that triage patients may shorten diagnostic delays
Early diagnosis, early treatment best in psoriatic arthritisDelayed diagnosis of PsA can lead to poor outcomes. Access to care elusive to some patients due to doctor shortage. Models of care that triage patients may shorten diagnostic delays.
Psoriasis and atopic dermatitis respond to IL-17 creamNitric oxide-releasing cream that targets IL-17 moving toward clinical trials.
Gene therapy trial for blistering skin condition advancing to next stage
Gene therapy trial for blistering skin condition advancing to next stageFCX-007 could be the first major medical advance for recessive dystrophic epidermolysis bullosa, or RDEB, in decades.
New psoriasis patient profileMetabolomics could provide new statistical methods to help monitor psoriasis disease and progression.
Biologic risk tolerance differs for pregnant patientsOf several biologic agents that women of reproductive age can choose from to treat and manage psoriasis, not all have the same safety profile during pregnancy and lactation periods.